As a commercial-stage medical device enterprise, CVRx faces several operational, financial, and regulatory risks that could impact its business trajectory. Key risks include ongoing net operating losses, historical cash burn rates, dependence on widespread physician adoption, and the complexities of securing broad insurance reimbursement across diverse healthcare jurisdictions. Additionally, the company faces competitive pressures from alternative heart failure device treatments, regulatory scrutiny regarding clinical trials, supply chain dependencies, and market volatility inherent to small-cap medical technology equities.